Guest Editorial
Volume 4 Issue 6 - 2020
Coronavirus Disease 2019 (COVID-19), Comorbidities, and Clinical Manifestations
Gundu HR Rao*
Emeritus Professor, Laboratory Medicine and Pathology, Director, Thrombosis, Lillehei Heart Institute, University of Minnesota, USA
*Corresponding Author: Gundu HR Rao, Emeritus Professor, Laboratory Medicine and Pathology, Director, Thrombosis, Lillehei Heart Institute, University of Minnesota, USA.
Received:May 23, 2020; Published: May 29, 2020




SARS CoV-2, the novel coronavirus has created an unprecedented pandemic worldwide. Covid-19 a highly contagious illness, is caused by a coronavirus of the type, that was first identified by Dr. Almeida in 1964, at her laboratory in St Thomas Hospital in London. In a very interesting investigative report, ‘titled, “Why weren’t We Ready for the Coronavirus?” David Quammen describes the reasons, why the US has fared worse than other countries. (The New Yorker -05/05/2020). The author asks a former scientist of Center for Disease Control (CDC) Dr. Khan about the preparedness, what went so disastrously wrong? Dr Ali Khan replies, “This is lack of imagination”. According to the latest disease prediction model, built by the researchers of Columbia University, if the country (USA) had locked down, two weeks earlier than it did on March 16th, it could have prevented 84% of deaths and 82% of cases (Pei: https://doi.org/10.1101/202.05.15.2010 3655). El Salvador’s president closed the border and implemented mitigation efforts, before a single case was reported from his country. According to Johns Hopkins Covid-19 tracker (coronavirus.jhu.edu), there have been 1571 confirmed cases and 31 deaths in this country. Similarly, the Vietnam’s success (324 confirmed cases and no deaths), is built on suppression of the virus, mitigation, and social distancing.

References

  1. Kamps BS and Hoffman C. “COVID Reference”. ENG (2020).
  2. Korber B., et al. “Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2”. Bio Rxiv (2020).
  3. Novokmet M., et al. “Understanding Glycans in COVID-19 Drug Design”. Genetic Engineering and Biotechnology (2020).
  4. Mehta N and Alter G. “Opportunities to exploit antibody glycosylation in vaccination”. Future Virology 12 (2017): 325-328.
  5. Ciaglia E., et al. “COVID-19 infection and circulating ACE2 levels: Protective Role in Women and Children”. Frontiers in Pediatrics (2020).
  6. Hamming I., et al. “Tissue distribution of ACE2 protein the functional receptor for SARS coronavirus. A first step in understanding the SARS pathogenesis”. The Journal of Pathology (2004) 203.
  7. Yang P., et al. “Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury”. Scientific Reports 4 (2014): 7027.
  8. Xu H., et al. “High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa”. International Journal of Oral Science (2020): 12.
  9. Sungnak W., et al. “Nasal epithelia cells together with innate immune genes”. Nature Medicine 26 (2020): 681-687.
  10. Liu Z., et al. “Implications of the virus-encoded miRNA and host miRNA in the pathogenicity of SARS-CoV-2”. arXiv (2004): 04874.
  11. Sadanand F., et al. “COVID-19 virulence in aged patients might be impacted by the host cellular MicroRNAs abundance/profile”. Aging and Disease3 (2020): 509-522.
  12. Sardar R., et al. “Comparative analyses of SAR-CoV2 genomes from different geographical locations and other coronavirus family genomes reveals unique feature potential consequential to host-virus interaction and pathogenesis”. Bio Rxiv (2020).
  13. Yao HL., et al. “Construction of miRNA-target networks using micro RNA profiles of CVB3-infected HeLa cells”. Scientific Reports (2019).
  14. Bai Y., et al. “Presumed asymptomatic carrier transmission of COVID-19”. The Journal of the American Medical Association14 (2020): 1406-1407.
  15. Wu Z and McGoogan JM. “Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72,314 cases from the Chinese Center for Disease Control and Prevention”. The Journal of the American Medical Association (2020).
  16. Richardson S., et al. “Presenting Characteristics, Comorbidities, and Outcomes among 5700 patients with COVID-19 in the New York City area”. The Journal of the American Medical Association (2020): e206775.
  17. Huang C., et al. “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China”. Lancet 395 (2020): 497-506.
  18. Chen N., et al. “Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study”. Lancet 395 (2020): 507-513.
  19. Wang D., et al. “Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China”. The Journal of the American Medical Association (2020).
  20. Wang B., et al. “Does comorbidity increase the risk of patients with COVID-19: Evidence from Meta-Analysis”. National Library of Medicines 7 (2020): 6049-6057.
  21. Xie J., et al. “Clinical characteristics of patients who died of coronavirus disease 20129 in China”. JAMA Network Open4 (2020): e205619.
  22. Guan WJ., et al. “China Medical Treatment Expert Group for Covid-19: Clinical Characteristics of Coronavirus Disease 2019 in China”. The New England Journal of Medicine (2020).
  23. Jiang F., et al. “Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19)”. Journal of General Internal Medicine (2020).
  24. Wang D., et al. “Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China”. The Journal of the American Medical Association (2020).
  25. Zhang JJ., et al. “Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China”. Allergy (2020).
  26. Xu XW., et al. “Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series”. British Medical Journal 368 (2020): m606.
  27. Guo T., et al. “Cardiovascular implications of fatal outcomes of patients with corona virus disease 2019(COVID-19)”. JAMA Cardiology (2020).
  28. Shi S., et al. “Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China”. JAMA Cardiology (2020).
  29. Kollias A., et al. “Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence for call for action”. Journal of the British Society for Haematology (2020).
  30. Bikdeli B., et al. “COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic therapy, and follow-up”. Journal of the American College of Cardiology 5 (2020): 531-538.
  31. Granlinski LE., et al. “Mechanisms of Severe Acute Respiratory Syndrome Coronavirus-Induced Acute Lung Injury”. mBio 4 (2013): e00271-e00213.
  32. Tang N., et al. “Anticoagulant treatment is associated with decreased mortality in severe coronavirus dieses 2019 patients with coagulopathy”. Journal of Thrombosis and Haemostasis 5 (2020): 1094-1099.
  33. Barnes BJ., et al. “Targeting potential drivers of Covid-19: Neutrophil extracellular traps”. Journal of Experimental Medicine 6 (2020): e20200652.
  34. Agnelli G., et al. “Apixaban for the treatment of venous thromboembolism associated with cancer”. The New England Journal of Medicine 382 (2020): 1599-1607.
  35. Singhal AB., et al. “Magnetic resonance spectroscopy study of oxygen therapy in ischemic stroke”. Stroke 38 (2007): 2851-2854.
  36. Chen R., et al. “The outcomes of Hyperbaric Oxygen Therapy to serve and critically ill patients with COVID-19 pneumonia” (2020).
  37. Zhong XL., et al. “Effect of hyperbaric oxygen therapy to treat hypoxia in Severe novel coronavirus pneumonia patients: First case report”. Chinese Journal of Integrative Medicine (2020).
  38. Harch PG. “Hyperbaric Oxygen Treatment of Novel Coronavirus ©VID-19) respiratory failure”. Commentary Medigen Gas Research (2020).
  39. Li B., et al. “Prevalence and impact of cardiovascular and metabolic diseases on COVID-19 in China”. Clinical Research in Cardiology 109 (2020): 531-538.
  40. Rao GHR. “COVID-19 and Cardiometabolic Diseases”. EC Cardiology6 (2020): 08-12.
  41. Rao GHR. “Coronavirus (COVID-19), Comorbidities, and Acute Vascular Events”. EC Clinical and Medical Case Reports6 (2020): 87-91.
  42. Guzik TJ., et al. “COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis and treatment”. Cardiovascular Research 106 (2020).
  43. Wu Z and McGoogan JM. “Characteristics and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center of Disease Control and Prevention”. The Journal of the American Medical Association (2020).
  44. Adao R and Guzik TJ. “Inside heart of COVID-19”. Cardiovascular Research (2020): cvaa086.
Citation: Gundu HR Rao. “Coronavirus Disease 2019 (COVID-19), Comorbidities, and Clinical Manifestations”. EC Diabetes and Metabolic Research 4.6 (2020): 27-33.

PubMed Indexed Article


EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005


EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777


EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347


EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478


EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253


EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033


EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992


EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505


EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793


EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211


EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047


EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560


EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318


EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819


EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840


EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344


EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476


EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658


EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489


EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278


EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108


EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571


EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333


EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883


EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001


EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937


EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723


EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726


EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603


EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646


EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616


EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290


EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226


EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812


EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268


News and Events


September Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the September issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for Upcoming Issue

ECronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before October 14, 2022.

Certificate of Publication

ECronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

ECronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.